HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luis Sánchez-Sánchez Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

3/2003NF-kappaB dependent activation of human endothelial cells treated with soluble products derived from human lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luis Sánchez-Sánchez Research Topics

Disease

11Neoplasms (Cancer)
08/2019 - 03/2003
6Uterine Cervical Neoplasms (Cancer of the Cervix)
02/2018 - 04/2010
1Starvation
03/2023
1Breast Neoplasms (Breast Cancer)
12/2017
1Lung Neoplasms (Lung Cancer)
12/2017
1Necrosis
12/2017
1Lymphoma (Lymphomas)
03/2003

Drug/Important Bio-Agent (IBA)

5Caspase 3 (Caspase-3)IBA
02/2018 - 04/2010
3DNA (Deoxyribonucleic Acid)IBA
03/2014 - 04/2010
2HeptanesIBA
02/2018 - 12/2017
2SteroidsIBA
03/2014 - 04/2010
2DiosgeninIBA
08/2012 - 04/2010
1Phosphatidylinositols (Phosphatidylinositol)IBA
03/2023
1EnzymesIBA
08/2019
1LactonesIBA
08/2019
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
08/2019
1Paclitaxel (Taxol)FDA LinkGeneric
02/2018
1Cisplatin (Platino)FDA LinkGeneric
02/2018
1CaspasesIBA
12/2017
1SapogeninsIBA
11/2016
1OximesIBA
11/2016
1phenylacetylrinvanilIBA
07/2015
1rinvanilIBA
07/2015
1Capsaicin (Zostrix)FDA Link
07/2015
1SeleniumIBA
03/2014
15-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA
04/2013
1Conditioned Culture MediaIBA
04/2013
1CytokinesIBA
04/2013
1SaltsIBA
08/2012
1GlycoconjugatesIBA
08/2012
1GlycosidesIBA
11/2010
1ChromatinIBA
11/2010
1hecogeninIBA
04/2010
1Interleukin-1beta (Interleukin 1 beta)IBA
03/2003
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2003
1NF-kappa B (NF-kB)IBA
03/2003